ProCE Banner Activity

Phase I Trial of Mosunetuzumab Bispecific Antibody in Multiply Relapsed Follicular Lymphoma

Slideset Download
Conference Coverage
Early-phase trial of mosunetuzumab suggests both high rates and durable responses in a cohort of patients with heavily pretreated FL, including in POD24 and double refractory disease.

Released: December 15, 2020

Expiration: December 14, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology